Actively Recruiting
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
Led by GERCOR - Multidisciplinary Oncology Cooperative Group · Updated on 2025-07-23
232
Participants Needed
16
Research Sites
181 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of Colorectal cancer liver metastasis.
CONDITIONS
Official Title
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and willing to follow all study procedures
- Age 18 years or older
- Histologically confirmed colorectal adenocarcinoma
- Primary tumor resected or eligible for resection within 6 months prior to inclusion
- Isolated colorectal liver metastases deemed resectable or potentially resectable (excluding most extrahepatic metastases)
- Eligible for surgery
- Fit for combined chemotherapy and surgery treatment
- Registered in a national health care system (including Protection Universelle Maladie)
You will not qualify if you...
- Definitively unresectable colorectal liver metastases
- More than 9 pre-operative chemotherapy cycles planned for metastatic disease
- Unresected primary rectal tumor (low and middle)
- History of another primary cancer within last 5 years (except specified skin and cervix cancers)
- More than two surgical procedures planned for complete resection of tumor and/or liver metastases
- Tumors with deficient mismatch repair or microsatellite instability treated with immunotherapy
- Unable to collect blood samples at surgery
- Pregnant or breastfeeding
- Unable to be followed up due to geographical, social, or psychological reasons
- Medical, psychiatric, or occupational issues preventing compliance
- Under guardianship, curatorship, or legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
CHU Jean Minjoz
Besançon, France
Not Yet Recruiting
2
Institut Bergonié
Bordeaux, France
Actively Recruiting
3
CHU Lille - Hôpital Huriez
Lille, France
Actively Recruiting
4
Centre Léon Bérard
Lyon, France
Actively Recruiting
5
Hôpital Bichât Claude Bernard
Paris, France
Not Yet Recruiting
6
Hôpital Cochin
Paris, France
Actively Recruiting
7
Hôpital Pitié Salpêtrière
Paris, France
Actively Recruiting
8
Hôpital Saint Antoine
Paris, France
Actively Recruiting
9
Institut Mutualiste Montsouris
Paris, France
Actively Recruiting
10
Hôpital Haut Lévêque
Pessac, France
Actively Recruiting
11
CHU de Poitiers
Poitiers, France
Actively Recruiting
12
CHU Rouen
Rouen, France
Not Yet Recruiting
13
CHU Strasbourg
Strasbourg, France
Actively Recruiting
14
CHRU Tours
Tours, France
Actively Recruiting
15
Hôpital Paul Brousse
Villejuif, France
Actively Recruiting
16
Institut Gustave Roussy
Villejuif, France
Actively Recruiting
Research Team
M
Maximiliano GELLI, MD
CONTACT
M
Marie Line GARCIA, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here